Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well preoperative (prior to surgery) radiation therapy with
fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) works for the treatment of stage
I-III esophageal or gastroesophageal junction adenocarcinoma. Hypofractionated radiation
therapy delivers higher doses of radiation therapy over a shorter period of time and may kill
more tumor cells and have fewer side effects. Fluorouracil stops cells from making
deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is not a chemotherapy
medication but is given in conjunction with chemotherapy. Leucovorin is used with the
chemotherapy medication fluorouracil to enhance the effects of the fluorouracil, in other
words, to make the drug work better. Oxaliplatin is in a class of medications called
platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor
cells. Giving preoperative hypofractionated radiation with fluorouracil and oxaliplatin may
kill more tumor cells in patients with stage I-III esophageal or gastroesophageal junction
adenocarcinoma.